Association of hsCAR With MAFLD and Liver Fibrosis: A Cross-sectional Study

Liver Fibrosis Clinical Trial

Official title: Association of High-sensitivity C-reactive Protein to Albumin Ratio With Metabolic Dysfunction-associated Fatty Liver Disease and Liver Fibrosis: A Cross-sectional Study

Status Recruiting

Clinical Trial Summary

The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic dysfunction-associated fatty liver disease (MAFLD).

The main question[s] it aims to answer are:

[question 1] Can hsCAR serve as a clinical indicator to determine whether a patient has MAFD? [question 2] Can hsCAR determine whether MAFLD patients are complicated with liver fibrosis?

Clinical Trial Description

Background Inflammation is related to the occurrence and development of fatty liver. Our research aimed to investigate the link between an inflammatory indicator, high-sensitivity C-reactive protein to albumin ratio (hsCAR), and metabolic dysfunction-associated fatty liver disease (MAFLD).

Methods Ultrasonic indices were used to evaluate the severity of liver steatosis and fibrosis of participants from the NHANES database, respectively. The relationship between hsCAR and MAFLD was explored using multivariate logistic regression analysis, restricted cubic splines (RCS) as well as threshold analysis. Finally, subgroup analyses were performed using the same methodology. ;

Related Conditions & MeSH terms

• Fatty Liver
• Fibrosis
• Hepatic Steatosis
• Liver Cirrhosis
• Liver Diseases
• Liver Fibrosis
• Non-alcoholic Fatty Liver Disease

• NCT number: NCT05974904
• Study type: Observational
• Source: Chongqing Medical University
• Contact: Tingqiu Wang, Bachelor
• Phone: +8617815370539
• Email: w857683014@163.com
• Status: Recruiting
• Start date: July 18, 2023
• Completion date: December 28, 2024